BioScrip Inc (NASDAQ:BIOS) shares were up 7.5% on Tuesday . The stock traded as high as $3.79 and last traded at $3.74. Approximately 1,041,775 shares changed hands during trading, an increase of 45% from the average daily volume of 716,155 shares. The stock had previously closed at $3.48.

Several research analysts recently weighed in on BIOS shares. Lake Street Capital lifted their price target on BioScrip from $4.50 to $10.00 and gave the company a “buy” rating in a research report on Friday, December 7th. Canaccord Genuity started coverage on BioScrip in a research report on Wednesday, December 12th. They set a “buy” rating and a $5.00 price target for the company. BidaskClub upgraded BioScrip from a “buy” rating to a “strong-buy” rating in a research report on Friday, September 21st. Barrington Research reiterated a “buy” rating and set a $4.00 price target on shares of BioScrip in a research report on Friday, October 5th. Finally, TheStreet upgraded BioScrip from a “d+” rating to a “c-” rating in a research report on Monday, November 26th. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $4.88.

The stock has a market cap of $437.90 million, a PE ratio of -9.21 and a beta of 0.61.

BioScrip (NASDAQ:BIOS) last announced its earnings results on Tuesday, November 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.02). The company had revenue of $181.00 million during the quarter, compared to analysts’ expectations of $171.35 million. During the same period in the previous year, the business posted ($0.12) earnings per share. The firm’s revenue for the quarter was down 8.9% on a year-over-year basis. As a group, research analysts predict that BioScrip Inc will post -0.33 EPS for the current fiscal year.

A number of institutional investors have recently bought and sold shares of BIOS. Metropolitan Life Insurance Co. NY lifted its position in BioScrip by 77.3% during the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 45,013 shares of the company’s stock worth $132,000 after acquiring an additional 19,625 shares during the period. Engineers Gate Manager LP acquired a new stake in BioScrip during the 3rd quarter worth approximately $146,000. MetLife Investment Advisors LLC lifted its position in BioScrip by 220.8% during the 2nd quarter. MetLife Investment Advisors LLC now owns 64,727 shares of the company’s stock worth $190,000 after acquiring an additional 44,548 shares during the period. Citadel Advisors LLC lifted its position in BioScrip by 471.9% during the 3rd quarter. Citadel Advisors LLC now owns 66,502 shares of the company’s stock worth $206,000 after acquiring an additional 54,874 shares during the period. Finally, B. Riley Wealth Management Inc. acquired a new stake in BioScrip during the 3rd quarter worth approximately $326,000. 82.09% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This piece of content was published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of US & international copyright & trademark laws. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/bioscrip-bios-trading-up-7-5/2737527.html.

About BioScrip (NASDAQ:BIOS)

BioScrip, Inc provides infusion solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. The company is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care.

Recommended Story: Preferred Stock

Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.